Elekta AB

Money comes from two linked streams: new equipment and software sold as bundled projects and paid out as they are delivered and accepted, and service and software-maintenance agreements tied to machines already in hospitals, typically renewed each year and often paid before the service is delivered. Even with a recurring stream layered on top of one-time equipment sales, its most recently reported full year still closed with a net loss, so this revenue mix has not by itself guaranteed profitability.

It sits among a very large population of companies whose production is organized around converting inputs into outputs at a physical, capped rate. Two different scaling logics run alongside each other: growth in output is tied to a small number of manufacturing sites in the United Kingdom, the Netherlands and China, while growth in service and software revenue rides on top of a device base that keeps generating work long after it is first installed, without requiring new factory capacity of its own. This second, installed-base logic is CompanyGraph's own reading of how the two disclosed revenue lines relate, rather than a mechanism the company describes in these terms.

Elekta's own account describes its inputs as specialized components, advanced technology, software capabilities and clinical expertise supplied by outside technology partners and research collaborators, including imaging-technology partners it names as Royal Philips and GE Healthcare, rather than raw materials it identifies by geographic origin. It also depends on regulatory clearance and on the hospitals and clinicians it works with to develop and validate its systems. CompanyGraph's broader mapping of industry relationships also places it downstream of a supplying industry.

Its customers are hospitals, cancer treatment centers and health systems, with clinicians and patients as the end users of its equipment. Its own disclosures show that no single buyer accounts for a large share of sales, so dependence on it runs across a broad, spread-out base of clinical sites rather than concentrating in a handful of large customers. CompanyGraph's own mapping of industry relationships places it upstream of several industries that draw on what it supplies.

In terms of how the underlying production system is built, this shape is shared by a very large number of other companies, so operating this way is not itself unusual. Elekta's own account points to the size of its installed base, the breadth of its combined equipment, software and service offering, and its use of open, interoperable software standards as what it considers its strengths, along with claims to leading positions in specific segments. These are the company's own claims about its position, not something CompanyGraph can confirm rivals are unable to match.

The initial purchase itself bundles the device together with software licenses, installation, training and a standard warranty into one project rather than a series of separate transactions, and what follows is a software maintenance and support relationship that its own account says is generally renewed on a yearly cycle, usually paid for in advance. This describes a contractual structure that continues the relationship after the sale, drawn from the company's own account of how its agreements are structured, rather than a measured rate of customers actually staying or leaving.

By its own account, Elekta says it is not yet performing at its full potential, and points to internal organizational complexity and layers of management, the speed of decisions and execution, how well it turns innovation into commercial products, its execution in the United States and China, and the cost of the goods it produces as the areas it is addressing. CompanyGraph separately classifies this kind of business, in general, as one where the capacity to convert inputs into finished equipment, and the cost of running that conversion, are the usual limits on growth. That general expectation lines up with the company's own mention of production cost, but has not been separately measured for Elekta specifically.

Elekta's own risk disclosures lead with the competitiveness and regulatory intensity of its industry, followed by exposure to corruption and improper payments, tariffs and sanctions, data-privacy and cyberattack incidents, technological disruption, and consolidation among the suppliers and customers it deals with. Its own disclosures also describe a recent internal review of booked but unfulfilled orders that led to part of that backlog being cancelled, and its most recently reported full year closed with a net loss, so at least part of what it names as a risk shows up in its own results rather than staying only hypothetical.

It operates under medical-device regulatory regimes in the United States, the European Union, Canada and Australia, all of which must clear its products before they can be sold. Its own risk disclosures put competitive and regulatory pressure first, followed by exposure to corruption and improper payments, tariffs and sanctions, data-privacy and cyberattack risk, technological disruption, and consolidation among both the suppliers and the customers it deals with. It also names exposure to several major currencies and to shifting trade policy, including tariff and sanctions regimes that can conflict with one another across the markets it sells into.